profit from every $100 of sales.
$0$100
BridgeBio Pharma
$78.17-1.72% today
+18.0% in 1 year
1-year low $63.301-year high $90.17
Trading in the middle of its range for the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average, 2020 to 2025.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What BridgeBio Pharma sold, what it kept, and what it did with the cash.
Sales went from $77.6 million in 2022 to $502 million in 2025, with -$725 million of profit last year.
SalesProfit
BridgeBio Pharma vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| BridgeBio Pharma | No profit yet | ||
 Vertex Pharmaceuticals | 34.8× · Expensive | ||
 Regeneron Pharmaceuticals | 21.8× · Fair price | ||
 Moderna | No profit yet | ||
 CSL | 22.3× · Fair price |
AI analysis
An AI analyst reads BridgeBio Pharma's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| 8 | 70 | 78 | 9 | 222 | 502 | |
| – | 67 | 74 | 7 | 218 | 481 | |
| -474 | -577 | -468 | -599 | -577 | -502 | |
| 544 | -534 | -397 | -565 | -437 | -549 | |
| -449 | -563 | -481 | -643 | -536 | -725 | |
| -3.80 | -3.90 | -3.26 | -3.95 | -2.88 | -3.78 | |
| – | 95.5% | 95.6% | 73.7% | 98.3% | 95.8% | |
| -5,752.0% | -827.1% | -603.3% | -6,443.6% | -260.2% | -100.0% | |
| -5,439.7% | -806.9% | -619.7% | -6,913.9% | -241.4% | -144.4% |
Balance sheet
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Total assets | 704 | 1,013 | 623 | 546 | 919 | 936 |
| Cash | 356 | 394 | 377 | 376 | 681 | 570 |
| Total debt | – | – | 1,724 | 1,740 | 1,731 | 1,862 |
| Total liabilities | 596 | 1,878 | 1,868 | 1,889 | 2,377 | 3,013 |
| 58 | -870 | -1,255 | -1,354 | -1,468 | -2,087 | |
| 118 | 144 | 147 | 163 | 186 | 192 | |
| 739.6% | – | -68.1% | -117.2% | -133.2% | – | |
| -774.9% | 64.6% | 38.4% | 47.5% | 36.5% | 34.7% |
Cash flow
| In millions of USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -400 | -498 | -419 | -528 | -521 | -446 | |
| – | – | 6 | 1 | 9 | 10 | |
| – | – | -426 | -529 | -530 | -456 | |
| Dividends paid | – | – | – | – | – | – |
| – | – | 2 | 7 | 8 | 63 | |
| 58 | 100 | 92 | 109 | 96 | 133 |
Valuation
- –
- –
- –
- -5.7×
- 30.3×
- –
- –
- -3.0%
- -4.8%
- 0.0%
Profitability
- 95.8%
- -100.0%
- -144.4%
- -103.6%
- -57.9%
- -130.2%
- 36.0%
- -52.9%
- -102.9%
- 85.0%
Growth
- +127.4%
- –
- +14.3%
- –
- +8.1%
Financial health
- –
- -1.49
- 246.9%
- -5.0×
- 1.44
- 1.40
- 0.42
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 5%of 952
Bottom 3%of 883
Top 4%of 870
Bottom 25%of 985
What analysts expect
- Average price target
- $100.58
- Range
- $83.00 – $157.00
- 9 analysts
These targets were collected on May 20, 2026 and our analyst feed has not updated since, so we no longer compare them with today's price.
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -0.84 | -0.70 | −20.0% |
| Feb 24, 2026 | -1.00 | -0.71 | −40.2% |
| Oct 29, 2025 | -0.95 | -0.88 | −8.0% |
| Aug 5, 2025 | -0.95 | -0.83 | −14.5% |
| Apr 29, 2025 | -0.88 | -1.00 | +12.0% |
| Feb 20, 2025 | -1.31 | -1.09 | −20.2% |
| Nov 12, 2024 | -0.86 | -1.03 | +16.5% |
| Aug 1, 2024 | -1.02 | -1.09 | +6.4% |
News
BridgeBio reports improved symptoms in Phase 3 trial of rare-disease drugSeeking Alpha · Oct 11, 2026Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
1/7Passes 1 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
20No pass
Benjamin Graham
18No pass
Philip Fisher
41No pass
Peter Lynch
62Pass
Joel Greenblatt
2No pass
Charlie Munger
33No pass
Terry Smith
31No pass
Questions about BridgeBio Pharma
Is BridgeBio Pharma a good stock to buy?
A business with weak numbers that is not profitable yet. 1 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the BridgeBio Pharma AI analysis
What does BridgeBio Pharma do?
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. It is in Biotechnology, based in Palo Alto, CA, United States, with 834 employees.
Does BridgeBio Pharma pay a dividend?
No. BridgeBio Pharma does not pay a dividend at the moment; in 2025 it returned $62.5 million to shareholders by buying back its own shares.
Is BridgeBio Pharma stock halal?
Yes. BridgeBio Pharma passes our halal screen: its business is permitted and its debt is 12% of its market value, under the 30% limit. How we check
How has BridgeBio Pharma stock done over the past year?
Up 18.0% over the past twelve months, to $78.17. It traded between $63.30 and $90.17 and is 13.3% below its high.
Who are BridgeBio Pharma's competitors?
The largest listed companies in the same industry are Vertex Pharmaceuticals, Regeneron Pharmaceuticals, Moderna and CSL. The peers table on this page compares their profit, growth and price with BridgeBio Pharma's.
Prices: daily closes to Nov 12, 2026. Fundamentals: company reports via invest-like data.